Headquartered in San Diego, California, the Cosmederm team is united in our goal to find novel solutions for inflammatory and autoimmune disease. Bringing together a unique blend of experience, our team facilitates a flexible and multi-faceted approach to innovation in our field. We live and breathe our mission daily, and uphold high standards both professionally and personally.
Chief Executive Officer
Mr. Pike has a long history in the area of healthcare and women’s reproductive health. He has taken drugs and devices through the FDA and been instrumental in making them commercially successful.
He served as the Chairman and CEO of Finishing Enterprises, Inc. (“FEI”) from 1987-1994. During that period, he introduced the Paraguard IUD into the U.S market and expanded sales and distribution of the company’s contraceptive products into over 100 countries. When J&J acquired U.S. distribution rights to its Paraguard, FEI was the world’s largest IUD manufacturer. He created joint ventures with Schering AG for Eastern Europe, and Hindustan Latex LTD., where he established an FDA compliant contraceptive, pharmaceutical, manufacturing plant in Travandrum, India. He also acquired contraceptive technologies from J&J and the Population Council and established Enhance Pharmaceuticals, which was sold to Barr Labs in 1992. Mr. Pike was also selected by the Population Council to take the controversial drug mifepristone (RU-486) through the FDA.
President and Chief Operating Officer
Mr. Eghbali Brings over 20 years of pharmaceutical and biotech experience to Cosmederm. Mr. Eghbali originally joined Cosmederm in 2014 as Vice President of Sales and Marketing, US and Global where he successfully launched the Refinity Skin Care franchise.
In July of 2015 with significant leadership changes Cosmederm promoted Mr. Eghbali to President and COO. He was asked to turn the company around. During his tenure as President and COO Mr. Eghbali has successfully helped Cosmederm get focused on Drug Development, out licensed the commercial assets and negotiated a buy back from the institutional investors putting the company back in the hands of private ownership.
Prior to joining Cosmederm Mr. Eghbali spent 16 years in Healthcare the bulk of which was spent at Allergan and Apria Healthcare.
Helen Tran, C.P.A.
Chief Financial Officer
Ms. Tran manages the financial, tax and accounting functions at Cosmederm. Previously she had a CPA practice and was a supervisor with Touche Ross &Co. (now Deloitte)
Helen has more than 30 of years experience in public accounting and private industry. While in private practice her clients included small businesses as well as major publicly-held corporations. She was an author and instructor of continuing education programs sponsored by the California Society of CPAs. She has also taught at the University of California, San Diego.
Siva Gudi, PhD
Director, Product Development
Dr. Gudi joined Cosmederm Biosciences in May 2014 as Chief Science Officer.
Prior to joining Cosmederm, Dr. Gudi served for more than 16 years in Product development leadership roles at Orexigen Therapeutics, Medicis Pharmaceuticals (Valeant Pharmaceuticals), Amylin Pharmaceuticals (AstraZeneca), Wochrdt USA and SkyePharma.
His expertise with pharmaceutical development of small molecules and biologics has contributed to regulatory approvals for Contrave®, Luzu®, Restylane®, Bydureon®, Myalept®, Byetta® and DepoDur®. Dr. Gudi received his Ph.D. in Biochemistry from the Central Drug Research Institute in India and his post-doctoral training from Penn State University and University of California, San Diego. Dr. Gudi is the author or co-author of over 20 peer-reviewed publications and given numerous scientific presentations.
Lee S. Simon, MD, FACP, FACR
Strategic Clinical Advisor
Dr. Simon is a Rheumatologist and has been the Division Director of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products (DAAODP) (2001-2003), within the Center for Drug Evaluation and Research (CDER), FDA.
He has been the recipient of several Quality Performance Awards and a Faculty Recognition Award from the FDA. He has served on and has been the Acting Chair of the Arthritis Advisory Committee of the DAAODP (1993-2001). He has also served on the advisory committees for the Division of Over the Counter Drugs (1996), Center for Devices (1995), and for the Division of Hematologic and Gastroenterologic Drug Products (1996). He has also served as a consultant for DDMAC (1993), the American Hospital Formulary (1990) and AMA Drug Products (1990). He is presently a Principal in SDG LLC, a consulting firm helping companies to create successful drug development programs through good designs and using insightful regulatory strategy (2004-).
He has been a clinical Rheumatologist for 25 years. He is a fellow of the American College of Physicians (1991) and the American College of Rheumatology (1986). Dr. Simon has had extensive experience in drug development in the US, and has served on consulting advisory boards for many different companies. This experience includes drugs and other therapeutics used for pain, anti-inflammatory effects, alteration of bone turnover, as well as modifying inflammatory disease states. He was a National Institutes of Health (NIH) funded investigator for 12 years working at the “wet bench” developing methodologies for in vitro measures approximating collagen turnover including the development of a commercial assay for measuring the carboxy-terminal portion of type I procollagen as a marker of new bone synthesis (1981-1993).
He has served for two terms on the Board of Directors of the American College of Rheumatology (ACR) (1991-1993, 1994-1997), served as the Chair of Education for the ACR and on the committee of the National Arthritis Foundation. He has served as the Scientific Abstract Selection Chair of the Annual Meeting of the ACR (2002). He has been awarded the 2003 Distinguished Service Award of the ACR and has been awarded the 2003 Scientific Leadership Award of the Lupus Research Institute. He served on the Steering Committee of IMPAACT, a group developing recommendations for the design and implementation of clinical trials investigating pain. He is on the Steering Committee and was Co-chair of the 2004 and 2012 OMERACT (Outcome Measures in Rheumatology) Biannual Meeting. OMERACT is a constituent group of the World Health Organization (WHO) through the International League of Associations of Rheumatology (ILAR). He served on the Steering Committee of the NIH Osteoarthritis Initiative (2001-2003). Dr. Simon has served as Chair of the biannual “Innovative Therapies in “Autoimmune Disease” conference sponsored by the ACR, FDA, NIH, and the Arthritis Foundation (2001-2005).
He has been on the editorial board of multiple journals and has authored more than 110 original publications, review articles and chapters, and has served as a co-editor of 4 books. He was Co-chair of the American Pain Society Guideline on the Treatment of Chronic Pain in Chronic Arthritis (1999-2001). He has presented on topics related to drug development, Rheumatology, the assessment and treatment of pain and bone disease. He served on the Scientific Advisory Committee of the National Osteoporosis Foundation, has been the Vice Chair of Medical Affairs of the Arthritis Foundation, Massachusetts Chapter as well as serving on its Board of Trustees (1992-2001). He was an Associate Professor of Medicine at Harvard Medical School (1995-2003) where he had been full time faculty since 1981, an Associate Chief of Medicine, Beth Israel Deaconess Medical Center (BIDMC) (1999-2001), Director of the Core Medicine Clerkship (1986-2000), Director of Clinical Rheumatology Research (1995-2001), Director of Graduate Medical Education at the BIDMC and the Deaconess Hospital (1989-2001), and Chair of Rehabilitation Services at the Deaconess Hospital (1986-1995), Harvard Medical School before joining the FDA. He served as a voluntary faculty member at Harvard and the BIDMC from 2004-2009 at which time he left to pursue a full time consulting practice in drug development and regulatory strategies.